Skip to content

Study · Animal study (in vivo) · mouse · 2021

6 results

Intranasal Carnosine Mitigates α-Synuclein Pathology and Motor Dysfunction in the Thy1-aSyn Mouse Model of Parkinson's Disease.

Brown JM, Baker LS, Seroogy KB, Genter MB

ACS chemical neuroscience17 Jun 2021Cited by 20 (Europe PMC)

PMID34138535 (opens in a new tab)PMCIDPMC9996643 (opens in a new tab)DOI10.1021/acschemneuro.1c00096 (opens in a new tab)PepBankPUB-34138535
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Thy1-aSyn mice, carnosine improved motor function dose-dependently.

    In plain wordsIn mice, motor function improved as carnosine doses increased from the vehicle dose.

    Peptide
    L-carnosine
    Outcome
    IncreaseMotor function
    Study

    mousen: not reported in source

    Thy1-aSyn mice
    Comparator
    Vehicle-treated Thy1-aSyn mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.0 or 4.0 mg/day · intranasal · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Behavioral assessments revealed a dose-dependent improvement in motor function with increasing carnosine dose.
    1 context sentence
    Summary · context
    After baseline neurobehavioral assessments, IN carnosine was administered (0.0, 2.0, or 4.0 mg/day) to wild-type and Thy1-aSyn mice for 8 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Thy1-aSyn mice, intranasal carnosine reduced SNpc alpha-synuclein-positive cell bodies versus vehicle.

    In plain wordsIn mice, carnosine reduced alpha-synuclein-positive cells in the SNpc compared with vehicle.

    Peptide
    L-carnosine
    Outcome
    DecreaseSNpc alpha-synuclein-positive cell bodies
    Study

    mousen: not reported in source

    Thy1-aSyn mice
    Comparator
    Vehicle-treated Thy1-aSyn mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.0 mg/day · intranasal · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Thy1-aSyn mice treated with 2.0 or 4.0 mg/d IN carnosine exhibited fewer aSyn-positive (aSyn(+)) cell bodies in the SNpc compared to vehicle-treated mice.
    1 context sentence
    Summary · context
    After baseline neurobehavioral assessments, IN carnosine was administered (0.0, 2.0, or 4.0 mg/day) to wild-type and Thy1-aSyn mice for 8 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In Thy1-aSyn mice, intranasal carnosine reduced SNpc alpha-synuclein-positive cell bodies versus vehicle.

    In plain wordsIn mice, carnosine reduced alpha-synuclein-positive cells in the SNpc compared with vehicle.

    Peptide
    L-carnosine
    Outcome
    DecreaseSNpc alpha-synuclein-positive cell bodies
    Study

    mousen: not reported in source

    Thy1-aSyn mice
    Comparator
    Vehicle-treated Thy1-aSyn mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    4.0 mg/day · intranasal · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Thy1-aSyn mice treated with 2.0 or 4.0 mg/d IN carnosine exhibited fewer aSyn-positive (aSyn(+)) cell bodies in the SNpc compared to vehicle-treated mice.
    1 context sentence
    Summary · context
    After baseline neurobehavioral assessments, IN carnosine was administered (0.0, 2.0, or 4.0 mg/day) to wild-type and Thy1-aSyn mice for 8 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In Thy1-aSyn mice, carnosine reduced SNpc alpha-synuclein-positive cell counts to vehicle-treated wild-type levels.

    In plain wordsIn mice, carnosine reduced SNpc alpha-synuclein-positive cell counts to the levels in vehicle-treated wild-type mice.

    Peptide
    L-carnosine
    Outcome
    No significant changeSNpc alpha-synuclein-positive cells relative to wild type
    Study

    mousen: not reported in source

    Thy1-aSyn mice
    Comparator
    Vehicle-treated wild-type mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Moreover, the number of aSyn(+) cell bodies in carnosine-treated Thy1-aSyn mice was reduced to vehicle-treated wild-type levels in the SNpc.
    1 context sentence
    Summary · context
    After baseline neurobehavioral assessments, IN carnosine was administered (0.0, 2.0, or 4.0 mg/day) to wild-type and Thy1-aSyn mice for 8 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In Thy1-aSyn mice, carnosine did not affect OB-MCL alpha-synuclein-positive cell counts.

    In plain wordsIn mice, carnosine did not change OB-MCL alpha-synuclein-positive cell counts compared with vehicle.

    Peptide
    L-carnosine
    Outcome
    No significant changeOB-MCL alpha-synuclein-positive cell bodies
    Study

    mousen: not reported in source

    Thy1-aSyn mice
    Comparator
    Vehicle-treated Thy1-aSyn mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Carnosine treatment did not affect the number of aSyn(+) cell bodies in the OB-MCL or the number of TH(+) cells in the SNpc.
    1 context sentence
    Summary · context
    After baseline neurobehavioral assessments, IN carnosine was administered (0.0, 2.0, or 4.0 mg/day) to wild-type and Thy1-aSyn mice for 8 weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In Thy1-aSyn mice, carnosine did not affect SNpc tyrosine hydroxylase-positive cell counts.

    In plain wordsIn mice, carnosine did not change SNpc tyrosine hydroxylase-positive cell counts compared with vehicle.

    Peptide
    L-carnosine
    Outcome
    No significant changeSNpc tyrosine hydroxylase-positive cells
    Study

    mousen: not reported in source

    Thy1-aSyn mice
    Comparator
    Vehicle-treated Thy1-aSyn mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Carnosine treatment did not affect the number of aSyn(+) cell bodies in the OB-MCL or the number of TH(+) cells in the SNpc.
    1 context sentence
    Summary · context
    After baseline neurobehavioral assessments, IN carnosine was administered (0.0, 2.0, or 4.0 mg/day) to wild-type and Thy1-aSyn mice for 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.